Kebernik J, et al. - To clarify the best course of antithrombotic therapy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), researchers assessed the efficacy and safety of dual therapy (DT) with novel oral anticoagulants (NOACs) plus a P2Y12 inhibitor as an alternative to guidelines-recommended triple therapy, which carries a high risk of bleeding. Following PCI, study participants were given DT with reduced doses of NOAC plus a P2Y12 inhibitor for 6 months, followed by standard dose NOAC monotherapy. Only 5.6% of 216 participants experienced efficacy events (including cardiac death, MI, stroke, and stent thrombosis) and there was no rebound of ischemic events noted after switching from DT to NOAC monotherapy after 6.3 ± 1.7 months. Findings demonstrated safety as well as efficacy for DT with NOAC and P2Y12 inhibitor followed by NOAC monotherapy in this long-term study of high-risk and real-world AF-patients with PCI.